Experimental study on mechanisms of lyophilized powder of fresh gekko Chinenis in inhibiting H22 hepatocarcinoma angiogenesis.
- Author:
Ping SONG
1
;
Xue-Mei WANG
;
Shuang XIE
Author Information
- Publication Type:Journal Article
- MeSH: Angiogenesis Inhibitors; pharmacology; Animals; Drugs, Chinese Herbal; pharmacology; Liver Neoplasms, Experimental; blood supply; pathology; Lizards; Materia Medica; Mice; Neovascularization, Pathologic; Tumor Cells, Cultured
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(1):58-62
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the inhibitory effects and its mechanism of lyophilized powder of fresh Gekko Chinenis (GCLP) on H22 hepatocarcinoma growth and angiogenesis in vitro.
METHODSThe transplant tumor model of H22 hepatocarcinoma in mice was established. Thirty mice were randomly divided into three groups, the cisplatin group, the GCLP group and the control group, they were treated respectively with intraperitoneal injection of cisplatin 1 mg/g, oral administration of GCLP in a dose of 1.2 g/kg, and equal volume of saline, the medication was given for 20 times totally. The anti-tumor activity was evaluated by tumor tissue weighing, the cell apoptotic rate was detected by TUNEL method, the micro-vessel density in tumor tissue was determined by Weidner method, the protein expression of vascular endothelin growth factor (VEGF) and basic fibroblast growth factor (bFGF) were detected by S-P immunohistochemistry.
RESULTSGCLP could obviously inhibit the hepatocarcinoma growth, induce tumor cell apoptosis, and reduce micro-vessel density in tumor tissue through down-regulating VEGF and bFGF protein expression.
CONCLUSIONSGCLP can effectively inhibit the growth of H22 hepatocarcinoma and angiogenesis. Its mechanism might be related to the down-regulation of the protein expression of VEGF and bFGF.